Disclaimer

This communication contains certain forward-looking statements, including, without limitation, statements containing the words "believes", "anticipates", "expects", "supposes", "considers" and words of similar import. Such forward-looking statements involve known and unknown risks, and certainties and other factors, which may cause the actual results, financial condition, performance, or achievements of Lumavita AG, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the early stage of the Company's development and uncertainties related to its technology, the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, the need for regulatory approval of the Company's operations and potential products, dependence on licenses, patents and proprietary technology, competition from other biotechnology, chemical and pharmaceutical companies, attraction and retention of technologically skilled employees, lack of sales and marketing structure and dependence on partners for commercialisation of potential products, limited manufacturing capabilities, management's discretion as to use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to health care reform, adverse changes in governmental rules and fiscal policies and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company and the authors of this communication disclaim any obligation to update any such forward-looking statements to reflect future events or developments.